NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its first quarter revenues rose 65 percent, driven in part by new placements of its ePlex analyzer in a flu season that generated strong testing demand.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $20.6 million, up from $12.5 million a year ago, and exceeding the consensus Wall Street estimate of $17.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.